Focal Therapy for Prostate Cancer Using HIFU (INDEX)

• ClinicalTrials.gov Identifier: NCT01194648
• Recruitment Status: Recruiting
• First Posted: September 3, 2010
• Last Update Posted: April 20, 2018
• Sponsor: University College, London
• Information provided by (Responsible Party): University College, London

Study Description

Brief Summary:

RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men achieving trifecta status (no erectile dysfunction, leak-free pad-free continence, cancer control). However, these trials have involved small numbers of patients with men selected for good baseline function. A multi-centre prospective trial within a larger cohort of men that better represents the patient population with prostate cancer (external validity) is required.

Condition or disease	Intervention/treatment	Phase
Male Erectile Disorder; Prostate Cancer; Therapy-related Toxicity; Urinary Incontinence	Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: multiparametric magnetic resonance imaging; Procedure: quality-of-life assessment; Procedure: transperineal prostate biopsy; Procedure: transrectal prostate biopsy	Not Applicable

Detailed Description:

Verification of a new therapy as favourable, or equivalent, in outcome to 'standard' care is ideally sought through comparison with another matched control group. Randomised controlled trials (RCTs) offer the best method for minimising systematic bias and revealing the true effect of an intervention or drug. However, RCTs involving treatments of localised prostate cancer have had a historically poor patient uptake, as the reference 'gold' standard of care is not known. In addition, RCTs are expensive to run and involve huge infra-structural support. A number of trials in the USA have been forced to close due to lack of recruitment. The ProStart trial in the UK has also had to close for the same reason. It has been acknowledged by the Food and Drug Agency in the USA that comparative randomized trials will be problematic in this area due to lack of physician and patient equipoise. A randomized trial may be feasible if a pragmatic design is adopted but prior to acceptance of such a design, the number of centres with expertise in this complex intervention (mp-MRI, TTPM, focal HIFU) will need to be increased.

Observational studies are a commonly used alternative to ascertain the effectiveness of a treatment. They are used to observe a treatment effect in a selected group of patients who are presumed to derive benefit from the treatment given. Although methodologically not as robust, and therefore prone to bias, they have some benefits over RCTs. The principal ones are those of enhanced external validity (many patients do not wished to be randomised and therefore refuse participation), and more rapid accrual compared to a randomised design. For this reasons, a single arm medium term follow-up cohort intervention study has been designed. At the time of writing the safety and tolerability aspects of focal therapy by HIFU are known as a result of the Phase I/II studies carried out at UCLH. The results have been presented and exist in the public domain in abstract form but have not yet been published (presented in tables above). These early studies were powered to detect a change in the proportion of men who could obtain an erection sufficient for penetration compared to their status prior to their treatment. The very low event rate for both erectile dysfunction and incontinence indicates that the 'proof of concept' has been demonstrated for focal therapy. Moreover, we can be relatively confident that, in expert hands, focal HIFU is safe. Therefore, a multi-centre study is now required involving a larger group of patients for the following reasons:

1. To evaluate medium term cancer control using histological parameters. Stage two of INDEX will evaluate conversion to radical and systemic therapies and link men to national databases to determine survival in 5 and 10 years.
2. To confirm that focal therapy can lead to low rates of genitourinary and rectal toxicity and minimal impact on quality of life within a large and more representative cohort of patients (greater precision around outcome measures).
3. To demonstrate that the skills (characterization through template prostate mapping and MRI as well as the treatment related skills) acquired by the team at UCLH are indeed transferable to other providers.
4. To calculate costs of care and to model potential cost-effectiveness in comparison to alternative therapies. If this single arm intervention study demonstrates acceptable outcomes to support the findings of the Phase I/II studies, it is anticipated that this preliminary study will lead onto a Phase III evaluation of focal therapy, prior to more widespread use of this technology.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 354 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Multi-Centre Prospective Single Arm Intervention Trial
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-Center Prospective Single Arm Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer
• Actual Study Start Date: June 29, 2011
• Estimated Primary Completion Date: December 2028
• Estimated Study Completion Date: June 2029

Arms and Interventions

Arm	Intervention/treatment
High Intensity Focused Ultrasound; HIFU, the Intervention	Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: multiparametric magnetic resonance imaging; Procedure: quality-of-life assessment; Procedure: transperineal prostate biopsy; Procedure: transrectal prostate biopsy

Outcome Measures

Primary Outcome Measures :

1. Conversion to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer [ Time Frame: 5 years ]
   To determine the proportion of men converting to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer following focal therapy for localised prostate cancer using HIFU
2. Conversion to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer [ Time Frame: 10 years ]
   To determine the proportion of men converting to radical therapy and/or requiring systemic therapy and/or developing metastases and/or dying of prostate cancer following focal therapy for localised prostate cancer using HIFU

Secondary Outcome Measures :

1. rate of erectile dysfunction [ Time Frame: 12 months ]
   The presence of severe erectile dysfunction at 12 months, as measured by the IIEF-5 questionnaire with or without the use of phosphodiesterase-5 inhibitors, in those with absence of severe erectile dysfunction at baseline
2. rate of erectile dysfunction [ Time Frame: 24 months ]
   The presence of severe erectile dysfunction at 24 months, as measured by the IIEF-5 questionnaire with or without the use of phosphodiesterase-5 inhibitors, in those with absence of severe erectile dysfunction at baseline
3. time to return of erectile function [ Time Frame: 24 months ]
   Time to return of erectile function (absence of severe ED on IIEF-15 questionnaire)
4. rate of urinary incontinence (pad free, leak free and pad-free alone) [ Time Frame: 12 months ]
   Presence of urinary incontinence (any pad usage plus any leakage of urine) as determined by the UCLA-EPIC urinary continence questionnaire, at 12 months, in those men with no urinary incontinence at baseline
5. rate of urinary incontinence (pad free, leak free and pad-free alone) [ Time Frame: 24 months ]
   Presence of urinary incontinence (any pad usage plus any leakage of urine) as determined by the UCLA-EPIC urinary continence questionnaire, at 24 months, in those men with no urinary incontinence at baseline
6. time to return of continence (pad free, leak free and pad-free alone) [ Time Frame: 24 months ]
   Time to return of urinary continence (as determined by UCLA-EPIC Urinary domain questionnaire)
7. rate of loss of ejaculation [ Time Frame: 24 months ]
   rate of loss of ejaculation (as determined by IIEF-15 questionnaire)
8. rate of loss of orgasm [ Time Frame: 24 months ]
   rate of loss of orgasm (as determined by IIEF-15 questionnaire)
9. rate of pain during intercourse [ Time Frame: 24 months ]
   rate of pain during intercourse (as determined by IIEF-15 questionnaire)
10. number of men using phosphodiesterase-5 inhibitors to maintain erectile function [ Time Frame: 24 months ]
    Need for phosphodiesterase-5 inhibitors to maintain erectile function sufficient for penetration up to 24 months
11. rate of lower urinary tract symptoms [ Time Frame: 24 months ]
    Grading of lower urinary tract symptoms as determined by IPSS scores
12. rate of bowel toxicity [ Time Frame: 24 months ]
    UCLA-EPIC Bowel Function Questionnaire
13. anxiety levels [ Time Frame: 24 months ]
    EQ-5D Quality of Life Questionnaire
14. general health related quality of life [ Time Frame: 24 months ]
    General and prostate health related quality of life measured using EQ-5D Quality of Life questionnaire
15. proportion of men achieving trifecta status at 12 months [ Time Frame: 12months ]
    Achievement of trifecta status (no severe ED, pad-free leak-free continence, cancer control with absence of clinically significant cancer) at 12 months in those men with good baseline function
16. proportion of men achieving trifecta status at 24 months [ Time Frame: 24 months ]
    Achievement of trifecta status (no severe ED, pad-free leak-free continence, cancer control with absence of clinically significant cancer) at 24 months in those men with good baseline function
17. rate of secondary prostate cancer intervention (prostatectomy, radiotherapy, androgen ablation, whole-gland HIFU or cryosurgery) [ Time Frame: 24 months ]
    rate of secondary prostate cancer intervention (prostatectomy, radiotherapy, androgen ablation, whole-gland HIFU or cryosurgery)
18. risk factors for failure defined as a) presence of any cancer and b) clinically significant cancer at study end [ Time Frame: 24 months ]
    risk factors for failure defined as a) presence of any cancer and b) clinically significant
19. biochemical (PSA) kinetics including determining the optimal biochemical definition of failure [ Time Frame: 24 months ]
    biochemical (PSA) kinetics including determining the optimal biochemical definition of
20. describe composite outcomes of failure [ Time Frame: 24 months ]
    describe composite outcomes of failure
21. Cost-effectiveness [ Time Frame: 5years ]
    To determine the costs of treatment and model potential cost effectiveness using comparative cancer control and functional outcomes at 5 years compared to other cohort trials involving the management of localized prostate cancer
22. Cost-effectiveness [ Time Frame: 10 years ]
    To determine the costs of treatment and model potential cost effectiveness using comparative cancer control and functional outcomes at 10 years compared to other cohort trials involving the management of localized prostate cancer

Eligibility Criteria

• Ages Eligible for Study: up to 90 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

1. Histologically proven prostate cancer on trans-rectal or transperineal template prostate biopsies.

2. Prostate biopsy (either TRUS or MRI Targeted or Template):

   • TRUS biopsy: up to burden bilateral disease with maximum 3mm one biopsy on non-dominant side is allowable.
   • MRI targeted and/or Template biopsy within 12 months of entry showing:
   • unilateral disease minimum 3mm of Gleason 3+3 or any Gleason 3+4 or 4+3 but not exceeding Gleason 4+3 overall OR
   • bilateral disease presence of clinically significant cancer on only one side (as determined by histological rules described above) Gleason ≤7 which is concordant with the MRI findings.
3. Stage T1-T2cN0M0 disease, as determined by local guidelines (radiological T3a permitted).
4. Serum PSA </=20ng/ml
5. Life expectancy of >/=10 years.
6. Signed informed consent by patient.
7. An understanding of the English language sufficient to understand

Contacts and Locations

Locations

United Kingdom

University College London; Recruiting

London, England, United Kingdom, WC1E 6BT

Contact: SITU Trials Unit +44207 679 9280 situ.index@ucl.ac.uk

Sponsors and Collaborators

University College, London

Investigators

• Study Chair: Mark Emberton, MD, FRCS, MBBS; University College, London
• Study Chair: Hashim Uddinn Ahmed, MD, FRCS; Imperial College London

More Information

• Responsible Party: University College, London
• ClinicalTrials.gov Identifier: NCT01194648
• Other Study ID Numbers: CDR0000684020; 9945 ( Other Grant/Funding Number: NIHR - CPMS ID )
• First Posted: September 3, 2010
• Last Update Posted: April 20, 2018
• Last Verified: April 2018

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University College, London:

urinary incontinence; male erectile disorder; therapy-related toxicity; stage I prostate cancer; stage IIB prostate cancer; stage IIA prostate cancer

Additional relevant MeSH terms:

Prostatic Neoplasms; Urinary Incontinence; Enuresis; Erectile Dysfunction; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Urination Disorders; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Lower Urinary Tract Symptoms; Urological Manifestations; Behavioral Symptoms; Elimination Disorders; Mental Disorders; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological